qr-110
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03140969)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Blindness · Phase 1/Phase 2
- Eye Diseases · Phase 1/Phase 2
- Eye Diseases, Hereditary · Phase 1/Phase 2
- Leber Congenital Amaurosis · Phase 1/Phase 2
- Neurologic Manifestations · Phase 1/Phase 2
- Optic Atrophy, Hereditary, Leber · Phase 1/Phase 2
- Retinal Diseases · Phase 1/Phase 2
- Sensation Disorders · Phase 1/Phase 2
- Vision Disorders · Phase 1/Phase 2
Mechanism of action
- Centrosomal protein of 290 kDaSupplementation
CEP290 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- qr-110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03913130 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2019 | ProQR Therapeutics |
| NCT03140969 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | ProQR Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ProQR Therapeutics | For profit | 2 | 2 | 1 | 2017 |
1 organizations
Page 1 / 1